Goldman Sachs Reinstates 4D Molecular Therapeutics (FDMT) at Buy, 'Platform value to inflect via 2024 catalysts'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/14/2026

1. CSCO
2. CBRS
3. COHR
4. SPY
5. NVDA
6. WYFI
7. STUB
8. ARX
9. EAT
10. BTGO

Go back to Goldman Sachs Reinstates 4D Molecular Therapeutics (FDMT) at Buy, 'Platform value to inflect via 2024 catalysts'

Form 424B5 4D Molecular Therapeutic

February 5, 2024 5:27 PM EST
Table of Contents

Filed Pursuant to Rule 424(b)(5)
Registration No. 333-276872

 

The information contained in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is... More

Form S-3ASR 4D Molecular Therapeutic

February 5, 2024 4:36 PM EST
Table of Contents

As filed with the Securities and Exchange Commission on February 5, 2024

Registration No. 333-     

 

 

... More